Anlon HealthcareNSE:AHCL 17 ROE % is 18.24% as of Mar. 2026, which is 55% below its 10-year median of 40.45. GuruFocus rates NSE:AHCL with a GF Score™ of 17/100. The stock has 5 warning signs investors should review. Among 935 Drug Manufacturers companies, Anlon Healthcare ranks better than 77.01% on this metric.
The historical rank and industry rank for Anlon Healthcare's ROE % or its related term are showing as below:
NSE:AHCL'
s ROE % Range Over the Past 10 Years
Min: -6.93 Med: 40.45 Max: 130.37
Current: 14.27
During the past 5 years, Anlon Healthcare's highest ROE % was 130.37%. The lowest was -6.93%. And the median was 40.45%.
NSE:AHCL's ROE % is ranked better than 77.01% of 935
companies
in the Drug Manufacturers industry
Industry Median: 6
vs NSE:AHCL: 14.27
Anlon Healthcare (NSE:AHCL) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Anlon Healthcare ROE % Related Terms
Anlon Healthcare ROE % Historical Data
* Premium members only.
The historical data trend for Anlon Healthcare's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Anlon Healthcare's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anlon Healthcare ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Anlon Healthcare's ROE % distribution charts can be found below:
* The bar in red indicates where Anlon Healthcare's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Anlon Healthcare (NSE:AHCL) has a ROE % of 18.24% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Anlon Healthcare and its competitors. This is 55% below median its historical median of 40.45. According to the industry distribution chart, Anlon Healthcare ranks #215 out of 935 companies in the Drug Manufacturers industry, placing it in the top 23%.
Is Anlon Healthcare's ROE % too high?
Anlon Healthcare's current ROE % of 18.24% is 55% below median its 10-year median of 40.45. The Drug Manufacturers industry median ROE % is 6.00. Anlon Healthcare's value of 18.24% is 204% above this industry median. Based on the distribution chart, Anlon Healthcare ranks #215 out of 935 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Anlon Healthcare has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Anlon Healthcare's ROE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Anlon Healthcare ranks #215 out of 935 companies for ROE %. This places Anlon Healthcare in the top 23% of its industry — outperforming the majority of peers. The industry median ROE % is 6.00. Anlon Healthcare's value of 18.24% is 204% above this benchmark. While the company's 10-year median is 40.45 vs. the industry median of 6.00, Anlon Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 6.00, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anlon Healthcare's current ROE % of 18.24% is 204% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Anlon Healthcare and its competitors. For the Drug Manufacturers industry, the median ROE % is 6.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anlon Healthcare's current ROE % is 18.24%, which is 55% below median its own 10-year median of 40.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anlon Healthcare stock overvalued right now?
Anlon Healthcare (NSE:AHCL) has a current ROE % of 18.24%. The current ROE % is 18.24%, which is 55% below median its 10-year median of 40.45 and 204% above the Drug Manufacturers industry median of 6.00. Anlon Healthcare's overall GF Score™ is 17/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Anlon Healthcare (NSE:AHCL), the current ROE % is 18.24% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anlon Healthcare Ltd is a chemical manufacturing company engaged in manufacturing of; (i) high purity advance pharmaceutical intermediates which serves as raw material/ key starting material in the manufacturing of active pharmaceutical ingredients; and (ii) active pharmaceutical ingredients which serves as a raw material for pharmaceutical formulations in preparation of various type of Finished Dosage Formula such as tablet, capsules, ointment, syrup etc, ingredients in nutraceuticals formulations, personal care products and animal health products. Its products spans across the family of pharmaceutical intermediates, active pharmaceutical ingredients, nutraceutical APIs and ingredients for personal care and veterinary API.
17GF Score
Get the complete analysis for NSE:AHCL
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AHCL has been successfully added to your 
